// App-Quantinova.ai

2009 : Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma

Researchers

Presenter

  • Adil Daud

Principal Investigators

  • Matteo S. Carlino

  • Antoni Ribas

  • Ana Arance

  • Jean-Jacques Grob

  • James Larkin

  • Georgina V. Long

  • Jacob Schachter

  • Andrea L. Webber

  • Clemens Krepler

  • Chunsheng Zhang

  • Jared Lunceford

  • Razvan Cristescu

  • Qing Zhao

  • Junshui Ma

  • Caroline Robert

Medical Centers

  • UCSF, San Francisco, CA

  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Aix-Marseille University, Hopital de la Timone, Marseille, France

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • Sheba Medical Center Hospital at Tel HaShomer, Tel-Hashomer, Israel

  • Merck & Co., Inc., Kenilworth, NJ

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

Locations

  • United States

  • Australia

  • Spain

  • France

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Granulin precursor

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01295827

  • NCT01866319

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved